发布求助
文献互助 智能选刊 最新文献

Cancer chemotherapy reports最新文献

筛选
英文 中文
Mathematic models for cancer chemotherapy: pharmacokinetic and cell kinetic considerations. 癌症化疗的数学模型:药代动力学和细胞动力学考虑。
Cancer chemotherapy reports Pub Date : 1975-07-01
S Chuang
{"title":"Mathematic models for cancer chemotherapy: pharmacokinetic and cell kinetic considerations.","authors":"S Chuang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This paper presents a theoretic study of pharmacokinetic and cell kinetic models for cancer chemotherapeutic systems. The mathematic analysis is based on a modified procedure deduced from DeVita's scheme of the relationship between the cellular kinetics of normal and tumor tissues and the pharmacokinetics of antitumor agents for designing an optimal dose and schedule for cancer treatment. In this scheme pharmacokinetic models and cell-drug interactions at the tumor site are incorporated into the cell cycle kinetic models to form the cancer chemotherapeutic model systems. Three cell cycle kinetic models are presented under alternative hypotheses concerning the mechanism of the resting cells, while each tumor mass is comprised of cells in proliferating (consisting of the four cycle phases G1, S, G2, and M), resting (Go), and non dividing (D, dead) states. An algorithm and a computer program for simulating the tumor populations during scheduled treatments have been prepared. By a suitable selection of expressions for cell-drug interactions, the program is able to simulate tumor behavior during scheduled treatments with different classes of anticancer agent such as cell cycle phase-specific, cell cycle-specific, or cell cycle-specific, or cell cycle-nonspecific drugs. A preliminary study of the L1210-ara-C therapeutic system is included to demonstrate the computer simulation procedures.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"827-42"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12352640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. 中、高剂量甲氨蝶呤(NSC-740)在人体的处置和代谢动力学模型。
Cancer chemotherapy reports Pub Date : 1975-07-01
P R Leme, P J Creaven, L M Allen, M Berman
{"title":"Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.","authors":"P R Leme,&nbsp;P J Creaven,&nbsp;L M Allen,&nbsp;M Berman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"811-7"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Contact dermatitis associated with adriamycin (NSC-123127) and daunorubicin (NSC-82151). 信函:接触性皮炎与阿霉素(NSC-123127)和柔红霉素(NSC-82151)相关。
Cancer chemotherapy reports Pub Date : 1975-07-01
S D Reich, N R Bachur
{"title":"Letter: Contact dermatitis associated with adriamycin (NSC-123127) and daunorubicin (NSC-82151).","authors":"S D Reich,&nbsp;N R Bachur","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"677-8"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma. ICRF-159 (NSC-129943)治疗晚期结直肠癌的II期研究
Cancer chemotherapy reports Pub Date : 1975-07-01
T A Marciniak, C G Moertel, A J Schutt, R G Hahn, R J Reitemeier
{"title":"Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.","authors":"T A Marciniak,&nbsp;C G Moertel,&nbsp;A J Schutt,&nbsp;R G Hahn,&nbsp;R J Reitemeier","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"761-3"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12280185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems. 左旋咪唑(NSC-177023)和四曲咪唑(NSC-102063)在实验性肿瘤系统中的作用。
Cancer chemotherapy reports Pub Date : 1975-07-01
R K Johnson, D P Houchens, M R Gaston, A Goldin
{"title":"Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems.","authors":"R K Johnson,&nbsp;D P Houchens,&nbsp;M R Gaston,&nbsp;A Goldin","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Levamisole and tetramisole had no antitumor effect against the following transplantable syngeneic murine tumors: L1210 leukemia, P388 leukemia, B16 melanoma, Madison 109 lung tumor, and Lewis lung carcinoma. In the Lewis lung carcinoma system there was no effect on primary tumor growth, metastasis, or survival. Tetramisole had a variable effect on the growth of rhabdomyosarcomas and the survival of BALB/c mice following intramuscular inoculation of Moloney sarcoma virus. In two experiments treatment with tetramisole either prior to or following inoculation of Moloney sarcoma virus increased the number of mice with tumor regression as opposed to progressive tumor growth, incrneased the number of long-term survivors, and prolonged the lifespan of mice that died of tumor. In two further tests neither levamisole nor tetramisole had an effect in this system. In mice immunosuppressed with cyclophosphamide prior to virus inoculation, there was not effect of treatment with levamisole or tetramisole.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"697-705"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations. 儿童癌症中的4’-去甲基表鬼臼毒素9-（4,6-o-2-亚乙基-β-D-葡糖苷）（NSC-122819；VM-26）和4’-脱甲基表鬼铃毒素9-（4.6-0-亚乙基-α-D-葡苷）（NSC-141540；VP-16-213）：初步观察。
Cancer chemotherapy reports Pub Date : 1975-07-01
G Rivera, T Avery, C Pratt
{"title":"4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.","authors":"G Rivera,&nbsp;T Avery,&nbsp;C Pratt","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We evaluated the responses of 39 children with cancer who, after failure to respond to conventional chemotherapeutic agents, received either or both of two epipodophyllotoxins: 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819) and 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene-beta-D-glucopyranoside) (NSC-141540). Seventeen patients has acute lymphocytic leukemia (ALL). 12 had acute nonlymphocytic leukemia (ANLL), and ten had solid tumors. Initially, the patients in each disease category were randomized to receive 50 mg/m2/dose of NSC-122819 intravenously (iv) twice weekly or 75 mg/m2/dose iv of NSC-141540 twice weekly for 4 weeks. Drug dosages and schedules of administration were adjusted during the course of the study. Although objective responses were not detected in the heterogeneous group of solid tumor patients, definite clinical responses were obtained in nine of the 29 patients with acute leukemia. The responses to the two epipodophyllotoxins were noted in patients with ALL as well as in patients with ANLL. Toxic side-effects included nausea, vomiting, diarrhea, fever, alopecia, leukopenia, and thrombocytopenia. These results, the first reported with both NSC-122819 and NSC-141540 in childhood cancer, indicate that the epipodophyllotoxins are well tolerated and may be effective against acute leukemia.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"743-9"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12280180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). 用ICRF-159 (NSC-129943)增强柔红霉素(NSC-82151)或阿霉素(NSC-123127)治疗早期小鼠L1210白血病的有效性
Cancer chemotherapy reports Pub Date : 1975-07-01
R J Woodman, R L Cysyk, I Kline, M Gang, J M Venditti
{"title":"Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).","authors":"R J Woodman,&nbsp;R L Cysyk,&nbsp;I Kline,&nbsp;M Gang,&nbsp;J M Venditti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The LD50 of intraperitoneally (ip) injected daunorubicin in nonleukemic mice (1.8 mg/kg, q4d times 3) can be increased several fold by the concomitant ip injection of ICRF-159. In addition, the survival of leukemic mice treated with daunorubicin and ICRF-159 on Days 1, 5, and 9 after ip inoculation of L1210 tumor cells was substantially greater than after treatment with either drug alone. This potentiation of survival with combination treatment usually occurred with doses of daunorubicin greater than the LD50 of daunorubicin alone. The LD50 of subcutaneously (sc) injected daunorubicin alone (14.0 mg/kg, q4d times 3) was not increased by concomitant ip treatment with ICRF-159. However, when leukemic mice were treated sc with daunorubicin and ip with ICRF-159 on Days 1, 5, and 9 after ip injection of L1210 leukemia cells, survival was greater than with treatment with either drug alone. The toxicity of ip injected adriamycin was not reduced by ICRF-159, but treatment of leukemic mice with this combination was more effective in prolonging survival than treatment with either drug alone. Combination treatment with daunorubicin plus ICRF-159 showed much less therapeutic enhancement against sc implanted L1210 leukemia than against the ip implanted tumor.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"689-95"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12351796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human pharmacokinetic model for isophosphamide (NSC-1097241). 异磷酰胺人药代动力学模型(NSC-1097241)。
Cancer chemotherapy reports Pub Date : 1975-07-01
L M Allen, P J Creaven
{"title":"Human pharmacokinetic model for isophosphamide (NSC-1097241).","authors":"L M Allen,&nbsp;P J Creaven","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"877-82"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12352642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stochastic compartmental modeling of the disposition of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). 5-(3,3-二甲基-1-三氮杂化)咪唑-4-羧酰胺(NSC-45388)配置的随机区室模型。
Cancer chemotherapy reports Pub Date : 1975-07-01
B McInnis, A Kapadia, S El-Asfouri, T L Loo
{"title":"Stochastic compartmental modeling of the disposition of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).","authors":"B McInnis,&nbsp;A Kapadia,&nbsp;S El-Asfouri,&nbsp;T L Loo","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"843-5"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12352644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetic considerations on resistance to anticancer drugs. 抗癌药物耐药的药代动力学研究。
Cancer chemotherapy reports Pub Date : 1975-07-01
R L Dedrick, D S Zaharko, R A Bender, W A Bleyer, R J Lutz
{"title":"Pharmacokinetic considerations on resistance to anticancer drugs.","authors":"R L Dedrick,&nbsp;D S Zaharko,&nbsp;R A Bender,&nbsp;W A Bleyer,&nbsp;R J Lutz","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A model framework is discussed for a quantitative description of intercompartment drug transport in terms of individual processes involved. It permits joint consideration of blood flow, membrane transport, binding, and enzyme synthesis. Illustrations are drawn from the pharmacokinetics and pharmacodynamics of methotrexate. Special cases include flow and membrane limitation, and a simple expression is derived to estimate the time required for intracellular drug to reach the concentration of high-affinity binding sites. Transport parameters between blood and cerebrospinal fluid are inferred from new clinical data. Lumbar injection provided a reservoir effect which maintained plasma concentration for a prolonged time compared with intravenous injections.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"795-804"},"PeriodicalIF":0.0,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12413789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信